© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 12, 1033-1039,
June 16, 1999
© 1999 Oxford University Press
Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part III: Quantifying the Link Between Population Prostate-Specific Antigen Testing and Recent Declines in Prostate Cancer Mortality
Affiliations of authors: R. Etzioni, Fred Hutchinson Cancer Research Center, Seattle, WA; J. M. Legler, E. J. Feuer, K. A. Cronin, B. F. Hankey, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD; R. M. Merrill, Health Sciences Department, Brigham Young University, Provo, UT.
Correspondence to: Ruth Etzioni, Ph.D., Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., MP-665, P. O. Box 19024, Seattle, WA 98109-1024 (e-mail: retzioni{at}fhcrc.org).
BACKGROUND: The objective of this study was to investigate the circumstances under which dissemination of prostate-specific antigen (PSA) testing, beginning in 1988, could plausibly explain the declines in prostate cancer mortality observed from 1992 through 1994. METHODS: We developed a computer simulation model by use of information on population-based PSA testing patterns, cancer detection rates, average lead time (the time by which diagnosis is advanced by screening), and projected decreased risk of death associated with early diagnosis of prostate cancer through PSA testing. The model provides estimates of the number of deaths prevented by PSA testing for the 7-year period from 1988 through 1994 and projects what prostate cancer mortality for these years would have been in the absence of PSA testing. RESULTS: Results were generated by assuming a level of screening efficacy similar to that hypothesized for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Under this assumption, the projected mortality in the absence of PSA testing continued the increasing trend observed before 1991 only when it was assumed that the mean lead time was 3 years or less. Projected mortality trends in the absence of PSA screening were not consistent with pre-1991 increasing trends for lead times of 5 years and 7 years. CONCLUSIONS: When screening is assumed to be at least as efficacious as hypothesized in the PLCO trial, it is unlikely that the entire decline in prostate cancer mortality can be explained by PSA testing based on current beliefs concerning lead time. Only very short lead times would produce a decline in mortality of the magnitude that has been observed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Draisma, R. Etzioni, A. Tsodikov, A. Mariotto, E. Wever, R. Gulati, E. Feuer, and H. de Koning Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context J Natl Cancer Inst, March 18, 2009; 101(6): 374 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Etzioni, R. Gulati, S. Falcon, and D. F. Penson Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach Med Decis Making, June 1, 2008; 28(3): 323 - 331. [Abstract] [PDF]
|
|
|
|
|
|
R. Kvale, A. Auvinen, H.-O. Adami, A. Klint, E. Hernes, B. Moller, E. Pukkala, H. H. Storm, L. Tryggvadottir, S. Tretli, et al. Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries J Natl Cancer Inst, December 19, 2007; 99(24): 1881 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Oberaigner, W. Horninger, H. Klocker, D. Schonitzer, W. Stuhlinger, and G. Bartsch Reduction of Prostate Cancer Mortality in Tyrol, Austria, after Introduction of Prostate-specific Antigen Testing Am. J. Epidemiol., August 15, 2006; 164(4): 376 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Thompson, D. P. Ankerst, C. Chi, M. S. Lucia, P. J. Goodman, J. J. Crowley, H. L. Parnes, and C. A. Coltman Jr Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower JAMA, July 6, 2005; 294(1): 66 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Bradley, K. I. Oravecz-Wilson, G. Bougeard, I. Mizukami, L. Li, A. J. Munaco, A. Sreekumar, M. N. Corradetti, A. M. Chinnaiyan, M. G. Sanda, et al. Serum Antibodies to Huntingtin Interacting Protein-1: A New Blood Test for Prostate Cancer Cancer Res., May 15, 2005; 65(10): 4126 - 4133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Brenner and V. Arndt Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis J. Clin. Oncol., January 20, 2005; 23(3): 441 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J Feuer, R. Etzioni, K. A Cronin, and A. Mariotto The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing Statistical Methods in Medical Research, December 1, 2004; 13(6): 421 - 442. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Shaw, R. Etzioni, S. B. Zeliadt, A. Mariotto, K. Karnofski, D. F. Penson, N. S. Weiss, and E. J. Feuer An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States Am. J. Epidemiol., December 1, 2004; 160(11): 1059 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. McNaughton-Collins, E. Walker-Corkery, and M. J. Barry Health-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 78 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sreekumar, B. Laxman, D. R. Rhodes, S. Bhagavathula, J. Harwood, D. Giacherio, D. Ghosh, M. G. Sanda, M. A. Rubin, and A. M. Chinnaiyan Humoral Immune Response to {alpha}-Methylacyl-CoA Racemase and Prostate Cancer J Natl Cancer Inst, June 2, 2004; 96(11): 834 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Draisma, R. Boer, S. J. Otto, I. W. van der Cruijsen, R. A. M. Damhuis, F. H. Schroder, and H. J. de Koning Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst, June 18, 2003; 95(12): 868 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Coldman, N. Phillips, and T. A. Pickles Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity Can. Med. Assoc. J., January 7, 2003; 168(1): 31 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xin, D. R. Rhodes, C. Ingold, A. M. Chinnaiyan, and M. A. Rubin Dysregulation of the Annexin Family Protein Family Is Associated with Prostate Cancer Progression Am. J. Pathol., January 1, 2003; 162(1): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harris and K. N. Lohr Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, December 3, 2002; 137(11): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu-Yao, P. C Albertsen, J. L Stanford, T. A Stukel, E. S Walker-Corkery, and M. J Barry Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ, October 5, 2002; 325(7367): 740 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kuefer, S. Varambally, M. Zhou, P. C. Lucas, M. Loeffler, H. Wolter, T. Mattfeldt, R. E. Hautmann, J. E. Gschwend, T. R. Barrette, et al. {alpha}-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation Am. J. Pathol., September 1, 2002; 161(3): 841 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Etzioni, D. F. Penson, J. M. Legler, D. di Tommaso, R. Boer, P. H. Gann, and E. J. Feuer Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends J Natl Cancer Inst, July 3, 2002; 94(13): 981 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rubin, M. Zhou, S. M. Dhanasekaran, S. Varambally, T. R. Barrette, M. G. Sanda, K. J. Pienta, D. Ghosh, and A. M. Chinnaiyan {alpha}-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer JAMA, April 3, 2002; 287(13): 1662 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Perron, L. Moore, I. Bairati, P.-M. Bernard, and F. Meyer PSA screening and prostate cancer mortality Can. Med. Assoc. J., March 1, 2002; 166(5): 586 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, and B. K. Edwards Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends J Natl Cancer Inst, June 6, 2001; 93(11): 824 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, W. Cozen, L. Bernstein, R. K. Ross, and D. Deapen Changing Relationship Between Socioeconomic Status and Prostate Cancer Incidence J Natl Cancer Inst, May 2, 2001; 93(9): 705 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Romano Re: Causes of Death in Elderly Prostate Cancer Patients and in a Comparison Nonprostate Cancer Cohort J Natl Cancer Inst, March 7, 2001; 93(5): 397 - 398. [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, S. J. Verselis, N. Klar, N. L. Sadowsky, C. M. Kaelin, B. Smith, L. Foretova, and F. P. Li Nipple Fluid Carcinoembryonic Antigen and Prostate-Specific Antigen in Cancer-Bearing and Tumor-Free Breasts J. Clin. Oncol., March 1, 2001; 19(5): 1462 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Hankey, L. A. Ries, and B. K. Edwards The Surveillance, Epidemiology, and End Results Program: A National Resource Cancer Epidemiol. Biomarkers Prev., December 1, 1999; 8(12): 1117 - 1121. [Full Text]
|
|
|
|
|
|
B. F. Hankey, E. J. Feuer, L. X. Clegg, R. B. Hayes, J. M. Legler, P. C. Prorok, L. A. Ries, R. M. Merrill, and R. S. Kaplan Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates J Natl Cancer Inst, June 16, 1999; 91(12): 1017 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Feuer, R. M. Merrill, and B. F. Hankey Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality J Natl Cancer Inst, June 16, 1999; 91(12): 1025 - 1032. [Abstract] [Full Text] [PDF]
|
|